As usual, the one-two punch of ASCO and BIO set us a bit behind, but never fear – your June hires round-up is here at least ...

In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable, about the company’s new digital-first model to handle ...

Nevertheless, there are issues here, too, with long waiting lists, resource constraints, and patient strife when attempting to access treatments and consultations. There are even problems with rising ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

The Cambridge, UK-headquartered company has said it will invest $50 billion in the US by 2030, with the centrepiece of its ...

The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...

The COVID-19 pandemic stopped the world in its tracks. It provided a range of new challenges for industry stakeholders, including governments, public health bodies, and regulatory agencies - to ...

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

Saultz and Lochner’s research have long highlighted how relational continuity enhances trust, communication, and shared ...

The FDA has a new director for the Center for Drug Evaluation and Research (CDER), with biopharma industry executive George ...